| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6291445 | ASTRAZENECA | Low dose budesonide formulations and uses thereof |
Apr, 2017
(7 years ago) | |
| US6686346 | ASTRAZENECA | Formulation |
Apr, 2017
(7 years ago) | |
| US6986904 | ASTRAZENECA | Formulation |
Apr, 2017
(7 years ago) | |
|
US6986904 (Pediatric) | ASTRAZENECA | Formulation |
Oct, 2017
(6 years ago) | |
|
US6686346 (Pediatric) | ASTRAZENECA | Formulation |
Oct, 2017
(6 years ago) | |
|
US6291445 (Pediatric) | ASTRAZENECA | Low dose budesonide formulations and uses thereof |
Oct, 2017
(6 years ago) | |
Rhinocort is owned by Astrazeneca.
Rhinocort contains Budesonide.
Rhinocort has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Rhinocort are:
- US6291445
- US6686346
- US6986904
- US6986904*PED
- US6686346*PED
- US6291445*PED
Rhinocort was authorised for market use on 01 October, 1999.
Rhinocort is available in spray, metered;nasal dosage forms.
Rhinocort can be used as nasal treatment of seasonal and perennial allergic rhinitis symptoms.
The generics of Rhinocort are possible to be released after 29 October, 2017.
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 01 October, 1999
Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms
Dosage: SPRAY, METERED;NASAL
RHINOCORT family patents
